Zynex, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 01, 2024 at 02:31 am IST
Share
Zynex, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 47.28 million compared to USD 48.81 million a year ago. Net income was USD 1.22 million compared to USD 7.45 million a year ago. Basic earnings per share from continuing operations was USD 0.04 compared to USD 0.2 a year ago. Diluted earnings per share from continuing operations was USD 0.04 compared to USD 0.2 a year ago.
For the full year, revenue was USD 184.32 million compared to USD 158.17 million a year ago. Net income was USD 9.73 million compared to USD 17.05 million a year ago. Basic earnings per share from continuing operations was USD 0.27 compared to USD 0.44 a year ago. Diluted earnings per share from continuing operations was USD 0.27 compared to USD 0.44 a year ago.
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Companyâs devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâs products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.